Delivery Order SPE2DB20D3303-SPE2DB25FA3WY
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $13,695.18 to AmerisourceBergen Drug Corp for Myrbetriq ER 50 mg tablets (90-count supply) on September 15, 2025, with completion targeted for September 16, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Myrbetriq is a prescription medication used to treat overactive bladder symptoms,...
- The Defense Logistics Agency awarded a delivery order valued at $7,904.97 to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (90-count packages). This firm fixed-price, non-set-aside contract was awarded on August 25, 2025, with an ultimate completion date of August 26, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Myrbetriq is a prescription medication used to treat overactive bladder, reflecting the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 22, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units) with a ceiling value of $38,427.53. This firm fixed-price, non-set-aside contract is classified as a delivery order and represents a single transaction under a larger contract vehicle. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of April 23, 2025....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for MYRBETRIQ ER 50 mg tablets (90 count) on September 10, 2025, with a ceiling value of $7,323.42 and firm fixed pricing. This non-set-aside, competitively awarded contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units) with a ceiling value of $36,782.80. This firm fixed-price delivery order, which has an ultimate completion date of August 12, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was not set-aside and was competitively awarded, with...
- The Defense Logistics Agency awarded a delivery order valued at $8,296.36 to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (90-count units). This is a firm fixed-price delivery order with no set-aside designation, competitively awarded and scheduled for completion by June 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Myrbetriq is a brand-name pharmaceutical product used to treat overactive...
- The Defense Logistics Agency awarded a $8,062.00 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units). This is a firm fixed-price delivery order with no set-aside designation, utilizing open competition. The contract is set to complete on August 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count) with a ceiling value of $5,024.66. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procedures. The contract requires completion by August 18, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Myrbetriq is a prescription medication...
- The Defense Logistics Agency awarded a delivery order valued at $3,683.89 to AmerisourceBergen Drug Corp for 90-count tablets of Myrbetriq ER 50 mg, a pharmaceutical product used in the treatment of overactive bladder. The contract, awarded September 4, 2025, with an ultimate completion date of September 5, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, fulfilled this order as part of its broader...
- The Defense Logistics Agency awarded a delivery order valued at $2,746.38 to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 50 mg, a medication commonly used to treat overactive bladder. The award was made on September 12, 2025, with an ultimate completion date of September 15, 2025, under a firm fixed-price contract type with no set-aside designation. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA3WYDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units) valued at $13,844.76. This is a firm fixed price delivery order with no set-aside designation, representing a competitively awarded transaction under AmerisourceBergen's existing contract vehicle with DLA. The order is scheduled for completion by September 19, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania location. Myrbetriq (mirabegron) is a prescription medication used to treat overactive bladder, indicating this procurement supports military healthcare needs for pharmaceutical treatment. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. AmerisourceBergen serves as a critical pharmaceutical distributor for federal medical procurement, supplying brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains to support military healthcare systems worldwide. The company's federal contracting activity demonstrates consistent capability to fulfill diverse medical supply requirements through competitive procurement processes and flexible contract mechanisms designed to meet the Defense Health Agency and other government healthcare systems' pharmaceutical needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.8k | 9/18/25 |